Neutralization activity and persistence of antibodies induced in response to vaccination with a novel mumps strain, RIT 4385.
We have previously shown that a new measles, mumps, rubella (MMR) vaccine, Priorix, with a novel mumps component elicits anti-mumps antibody titers comparable to the licensed M-M-R II vaccine. To ensure that these antibodies had neutralizing activity against wild-type mumps virus, sera were prepared 2 and 18 months after vaccination of 12-24-month-old infants with either Priorix or M-M-R II and ELISA antibody titers and neutralizing activity were determined. After 2 months, Priorix and M-M-R II vaccines elicited comparable ELISA antibody titers and neutralizing activity. At 18 months ELISA seropositivity rates were 80-81% and 94-96% of vaccinees had neutralizing activity. All ELISA seropositives had neutralizing activity. These data suggest that both vaccines provided equivalent protection against mumps over this 18-month period.